|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 201.18 USD | +8.53% |
|
+11.84% | +14.31% |
| 02-06 | Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating | MT |
| 02-06 | Biogen Inc., Q4 2025 Earnings Call, Feb 06, 2026 |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 9.89B | 13.07% | 28.69% | 12.53% | 6.65% | 0.55x | ||
| 14.34B | 31.41% | 34.05% | 16.13% | 12.48% | -1.17x | ||
| 15.56B | 19.3% | 28.72% | 16.36% | 7.75% | 1.74x | ||
| 6.37B | 17.31% | 13.59% | 11.21% | 6.48% | 0.99x | ||
| 3.08B | 23.82% | 29.03% | 10.45% | 6.49% | 0.1x | ||
| 4.24B | 0.77% | 9.76% | 5.27% | 3.72% | -4.29x | ||
| 1.29B | -1% | -8.02% | -0.74% | -0.45% | -11.4x | ||
| 3.24B | -110.04% | -121.91% | -28.77% | -21.87% | 1.87x | ||
| 2.35B | 14.93% | 22.42% | 10.9% | 5.41% | 1.59x | ||
| 681M | -10.97% | -17.14% | -8.58% | -7.13% | 8.63x | ||
| 69.63M | 59.01% | 24.7% | 28.77% | 18.72% | -6.16x | ||
| 222M | -241.44% | -267.22% | 35.11% | -73.11% | -1.77x | ||
| 2.85B | 14.96% | 16.97% | 8.05% | 6.17% | -0.93x | ||
| 10.9M | -2,957.71% | -3,477.43% | -33.47% | - | 3.99x | ||
| 386M | -74.47% | -72.74% | -231.63% | -49.66% | 0.49x | ||
| 7.47B | 2.18% | 18.81% | 2.79% | 0.74% | 5.16x | ||
| 291M | 30.69% | 22.61% | 10.34% | - | -8.45x | ||
| 308M | 4.73% | 4.18% | 0.85% | - | -5.29x | ||
| 1.25B | 22.95% | 28.06% | 14.19% | 8.74% | 0.28x | ||
| Average | 3.89B | -165.29% | -193.84% | -6.33% | -4.3% | -0.74x | |
| Weighted average by Cap. | 7.15B | -66.46% | -77.78% | 4.85% | 2.5% | -0.34x |
- Stock Market
- Equities
- BIIB Stock
- Sector Biogen Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















